

Naomi J Winick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5571589/publications.pdf>

Version: 2024-02-01

175
papers

10,315
citations

53751

45
h-index

36008

97
g-index

176
all docs

176
docs citations

176
times ranked

10136
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia. <i>Infection Control and Hospital Epidemiology</i> , 2023, 44, 222-229.	1.0	1
2	Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232. <i>Leukemia</i> , 2022, 36, 648-655.	3.3	14
3	Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. <i>Cancer</i> , 2022, 128, 1863-1870.	2.0	12
4	Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. <i>Haematologica</i> , 2022, 107, 1205-1208.	1.7	11
5	Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1167-1175.	3.0	6
6	Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. <i>Blood</i> , 2021, 137, 1550-1552.	0.6	3
7	Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2021, 113, 408-417.	3.0	16
8	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 504-512.	2.5	28
9	Adaptive functioning and academic achievement in survivors of childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28913.	0.8	6
10	Reply to A. K. Agrawal et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 695-696.	0.8	0
11	FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. <i>Leukemia</i> , 2021, 35, 1279-1290.	3.3	46
12	Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28929.	0.8	9
13	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 794-802.	2.3	7
14	Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. <i>Journal of Clinical Oncology</i> , 2021, 39, 1437-1447.	0.8	56
15	Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. <i>Journal of Clinical Oncology</i> , 2021, 39, 1540-1552.	0.8	19
16	Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia. <i>Lancet Haematology</i> , 2021, 8, e513-e523.	2.2	14
17	Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma. <i>Blood Advances</i> , 2021, 5, 2890-2900.	2.5	3
18	Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children's Oncology Group study AALL02P2. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29256.	0.8	10

#	ARTICLE	IF	CITATIONS
19	Disparities in Cancer Survival Among Adolescents and Young Adults: A Population-Based Study of 88â€‰%000 Patients. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1074-1083.	3.0	32
20	The impact of family bereavement interventions: Qualitative feedback identifies needs.. <i>Clinical Practice in Pediatric Psychology</i> , 2021, 9, 283-295.	0.2	2
21	Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia. <i>JAMA Network Open</i> , 2021, 4, e2128385.	2.8	6
22	Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report. <i>Blood</i> , 2021, 138, 2382-2382.	0.6	0
23	Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study. <i>Blood</i> , 2021, 138, 211-211.	0.6	3
24	Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905. <i>Leukemia</i> , 2020, 34, 1006-1016.	3.3	8
25	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. <i>Journal of Clinical Oncology</i> , 2020, 38, 602-612.	0.8	107
26	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3282-3293.	0.8	136
27	A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies. <i>Pediatric Hematology and Oncology</i> , 2020, 37, 465-474.	0.3	12
28	Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. <i>Journal of Clinical Oncology</i> , 2020, 38, 2628-2638.	0.8	41
29	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. <i>Journal of Clinical Oncology</i> , 2020, 38, 3062-3070.	0.8	42
30	Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433. <i>Haematologica</i> , 2020, 106, 46-55.	1.7	29
31	Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 1897-1905.	0.8	117
32	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2020, 136, 44-45.	0.6	1
33	Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report. <i>Blood</i> , 2020, 136, 39-40.	0.6	2
34	Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report. <i>Blood</i> , 2020, 136, 38-39.	0.6	0
35	Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. <i>Cancer Genetics</i> , 2019, 238, 62-68.	0.2	32
36	Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. <i>Blood</i> , 2019, 134, 1227-1237.	0.6	37

#	ARTICLE	IF	CITATIONS
37	Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4. <i>Leukemia and Lymphoma</i> , 2019, 60, 1740-1748.	0.6	25
38	Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2019, 104, e517-e520.	1.7	11
39	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27681.	0.8	8
40	1740. Title: Outcomes of a Clinical Algorithm for the Early Diagnosis and Treatment of Invasive Fungal Sinusitis among Children with Hematologic Malignancy or Prior Hematopoietic Stem Cell Transplantation. <i>Open Forum Infectious Diseases</i> , 2019, 6, S637-S637.	0.4	0
41	Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1421-1428.	2.3	28
42	Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. <i>Haematologica</i> , 2019, 104, 986-992.	1.7	25
43	Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. <i>Blood</i> , 2019, 133, 724-729.	0.6	44
44	Home or Away from Home: A Multi-Institution Study Comparing Medical Outcomes, Patient Perspectives, and Health-Related Quality of Life for Outpatient Versus Inpatient Management after Chemotherapy for Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 379-379.	0.6	1
45	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). <i>Leukemia</i> , 2018, 32, 1370-1379.	3.3	40
46	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2018, 33, 937-948.e8.	7.7	142
47	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. <i>Cancer</i> , 2018, 124, 1150-1159.	2.0	46
48	Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26928.	0.8	28
49	Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. <i>Cancer</i> , 2018, 124, 571-579.	2.0	31
50	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. <i>Journal of Clinical Oncology</i> , 2018, 36, 2306-2314.	0.8	185
51	<i>TP53</i> Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. <i>Journal of Clinical Oncology</i> , 2018, 36, 591-599.	0.8	121
52	Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky069.	1.4	10
53	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. <i>Journal of Clinical Oncology</i> , 2018, 36, 2926-2934.	0.8	164
54	Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131. <i>Blood</i> , 2018, 132, 35-35.	0.6	7

#	ARTICLE	IF	CITATIONS
55	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434. <i>Blood</i> , 2018, 132, 659-659.	0.6	0
56	Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	64
57	Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26636.	0.8	23
58	Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation. <i>Nature Medicine</i> , 2017, 23, 79-90.	15.2	101
59	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2017, 49, 1211-1218.	9.4	693
60	Klinefelter syndrome and 47,<sc>XYY</sc> syndrome in children with B cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2017, 179, 843-846.	1.2	4
61	Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG). <i>Leukemia</i> , 2017, , .	3.3	1
62	Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 2700-2707.	0.8	38
63	Reply to I.J. Cohen. <i>Journal of Clinical Oncology</i> , 2017, 35, 3989-3991.	0.8	2
64	Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 2527-2534.	0.8	64
65	Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia—Comparison among Different Treatment Strategies. <i>Pediatric Blood and Cancer</i> , 2016, 63, 255-261.	0.8	17
66	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. <i>Journal of Clinical Oncology</i> , 2016, 34, 2380-2388.	0.8	301
67	Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 2133-2140.	0.8	88
68	Application of a standardized screening protocol for diagnosis of invasive mold infections in children with hematologic malignancies. <i>Supportive Care in Cancer</i> , 2016, 24, 5025-5033.	1.0	14
69	CD25 Expression in B Lymphoblastic Leukemia/Lymphoma Predicts t(9;22)(q34;q11)/Philadelphia Chromosome Translocation (Ph) and Is Associated With Residual Disease in Ph-Negative Patients. <i>American Journal of Clinical Pathology</i> , 2016, 146, 632-638.	0.4	6
70	Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study <sc>AALL0331</sc>. <i>International Journal of Cancer</i> , 2016, 138, 332-339.	2.3	66
71	Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the <sc>C</sc>hildren's <sc>O</sc>nology <sc>G</sc>roup. <i>Cancer</i> , 2016, 122, 1116-1125.	2.0	72
72	Comprehensive Functional Characterization of Germline ETV6 Variants Associated with Inherited Predisposition to Acute Lymphoblastic Leukemia in Children. <i>Blood</i> , 2016, 128, 1085-1085.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome. <i>Blood</i> , 2016, 128, 1086-1086.	0.6	2
74	Anti-Pegaspargase, Anti-Calaspargase Pegol , and Anti-Polyethelene Glycol Antibody Incidence in High Risk Acute Lymphoblastic Leukemia Patients Receiving Pegaspargase or Calaspargase Pegol and Associated Anaphylactic or Hypersensitivity Reaction Rates: Results from Children's Oncology Group (COG) Study AALL07P4. <i>Blood</i> , 2016, 128, 3965-3965.	0.6	5
75	Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 451-451.	0.6	4
76	General Adaptive Functioning in Survivors of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 4770-4770.	0.6	1
77	Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2016, 128, 758-758.	0.6	1
78	Germline Genetic Variation in IKZF1 and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, LBA-2-LBA-2.	0.6	3
79	Integrated Genomic Analysis of Down Syndrome Acute Lymphoblastic Leukemia Reveals Recurrent Cancer Gene Alterations and Evidence of Frequent Subclonal Driver Events. <i>Blood</i> , 2016, 128, 4083-4083.	0.6	0
80	New Insights into Deregulated Gene Expression Pathways in MLL- and AF10-Rearranged T-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 2906-2906.	0.6	0
81	Evaluation of Minimal Residual Disease As a Surrogate Endpoint for Event Free Survival in Childhood B-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 759-759.	0.6	0
82	Whole Exome Sequencing of Pediatric Acute Lymphoblastic Leukemia Patients Identify Mutations in 11 Pathways: A Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 455-455.	0.6	1
83	Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: A report from the children's oncology group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 414-418.	0.8	31
84	Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. <i>Blood</i> , 2015, 126, 964-971.	0.6	287
85	Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 1770-1776.	0.6	102
86	The evolution of central nervous system prophylaxis for patients with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1877-1878.	0.8	1
87	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1176-1183.	0.8	76
88	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. <i>Blood</i> , 2015, 126, 69-75.	0.6	64
89	Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. <i>Pediatric Blood and Cancer</i> , 2015, 62, 123-127.	0.8	52
90	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. <i>Nature Communications</i> , 2015, 6, 7553.	5.8	72

#	ARTICLE	IF	CITATIONS
91	Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3). <i>Pediatric Blood and Cancer</i> , 2015, 62, 419-426.	0.8	61
92	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. <i>Lancet Oncology</i> , The, 2015, 16, 1659-1666.	5.1	161
93	Incidence of Allergic Reactions to Pegaspargase (PEG) Administered Intramuscularly Versus Intravenously (IM vs. IV) in Children and Young Adults with High Risk B-Lymphoblastic Leukemia (HR Tj ETQq1 1 0.784314 rgBT /Over 1303-1303.	0.6	6
94	The Genomic Landscape of Childhood T-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 691-691.	0.6	4
95	Mixed Lineage Leukemia Rearrangements (MLL-R) Are Determinants of High Risk Disease in Homeobox A (HOXA)-deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Blood</i> , 2015, 126, 694-694.	0.6	2
96	Capizzi-Style Methotrexate with Pegaspargase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434. <i>Blood</i> , 2015, 126, 794-794.	0.6	12
97	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2015, 126, 807-807.	0.6	5
98	Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 695-695.	0.6	2
99	Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol <i>Escherichia coli</i> L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4. <i>Journal of Clinical Oncology</i> , 2014, 32, 3874-3882.	0.8	91
100	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 1005-1015.	13.9	1,161
101	HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. <i>Blood</i> , 2014, 124, 1266-1276.	0.6	84
102	It takes a village. <i>Blood</i> , 2014, 124, 2316-2317.	0.6	7
103	T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children's Oncology Group (COG) Study AALL0434. <i>Blood</i> , 2014, 124, 1-1.	0.6	113
104	Effect of High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Pegaspargase (C-MTX/ASNase) on Osteonecrosis (ON) Incidence in Children and Young Adults with T-Acute Lymphoblastic Leukemia (T-ALL): Results of Children's Oncology Group (COG) Study AALL0434. <i>Blood</i> , 2014, 124, 3649-3649.	0.6	5
105	Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis. <i>Blood</i> , 2014, 124, 367-367.	0.6	1
106	A Phase I Dose Finding Study of Panobinostat in Children with Hematologic Malignancies: Initial Report of TACL Study T2009-012 in Children with Acute Leukemia. <i>Blood</i> , 2014, 124, 3705-3705.	0.6	8
107	Outcomes after Intermediate-Risk Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) and the Role of Allogeneic Stem Cell Transplantation (SCT): A Report from Children's Oncology Group (COG) AALL0433. <i>Blood</i> , 2014, 124, 684-684.	0.6	4
108	Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children's Oncology Group (COG) Study AALL0331. <i>Blood</i> , 2014, 124, 793-793.	0.6	15

#	ARTICLE	IF	CITATIONS
109	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. <i>Blood</i> , 2014, 124, 63-63.	0.6	6
110	Resource Utilization and Cost Analysis By Treatment Arm on the Children's Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Children's Oncology Group. <i>Blood</i> , 2014, 124, 210-210.	0.6	0
111	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. <i>Blood</i> , 2013, 121, 485-488.	0.6	156
112	Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2013, 60, 957-963.	0.8	149
113	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. <i>Nature Genetics</i> , 2013, 45, 1494-1498.	9.4	264
114	Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. <i>Journal of the National Cancer Institute</i> , 2013, 105, 733-742.	3.0	208
115	Genome-wide study of methotrexate clearance replicates SLCO1B1. <i>Blood</i> , 2013, 121, 898-904.	0.6	174
116	Genomic Characterization and Experimental Modeling Of BCR-ABL1-Like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 232-232.	0.6	8
117	Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance). <i>Blood</i> , 2013, 122, 3903-3903.	0.6	35
118	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 60-60.	0.6	1
119	Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 618-618.	0.6	6
120	Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome. <i>Blood</i> , 2013, 122, 825-825.	0.6	8
121	Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (Ph-like) or BCR-ABL1-Like Signature For Therapeutic Targeting and Clinical Intervention. <i>Blood</i> , 2013, 122, 826-826.	0.6	65
122	Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Children's Oncology Group (COG) AALL0331. <i>Blood</i> , 2013, 122, 837-837.	0.6	13
123	Risk Factors For Acute Pancreatitis In Patients With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 3868-3868.	0.6	0
124	A Strategy For Early Diagnosis Of Invasive Mold Infections In Children With Hematologic Malignancies. <i>Blood</i> , 2013, 122, 2959-2959.	0.6	0
125	<i>ARID5B</i> Genetic Polymorphisms Contribute to Racial Disparities in the Incidence and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 751-757.	0.8	165
126	Pilot Study of Nelarabine in Combination With Intensive Chemotherapy in High-Risk T-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 2753-2759.	0.8	82

#	ARTICLE	IF	CITATIONS
127	Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. <i>Blood</i> , 2012, 119, 1872-1881.	0.6	110
128	Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. <i>Blood</i> , 2012, 120, 4197-4204.	0.6	103
129	Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 1663-1669.	0.8	944
130	Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622. <i>Blood</i> , 2012, 120, 137-137.	0.6	7
131	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.. <i>Blood</i> , 2012, 120, 2466-2466.	0.6	5
132	Identification of CRLF2 Genomic Lesions in Patients with Pediatric B-Precursor Acute Lymphoblastic Leukemia (BCP ALL) by Flow Cytometry or Quantitative RT-PCR: A Children's Oncology Group (COG) Stud.. <i>Blood</i> , 2012, 120, 2529-2529.	0.6	10
133	Effects of Dexamethasone (DEX) Vs Prednisone (PDN) and High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Asparaginase (C-MTX/ASNase) On Osteonecrosis (ON) Incidence in Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From the Children's Oncology Group (COG) Study AALL0232. <i>Blood</i> , 2012, 120, 665-665.	0.6	3
134	Genome-Wide Association Study Identifies Germline Polymorphisms Associated with Relapse of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 878-878.	0.6	0
135	Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. <i>Blood</i> , 2012, 120, 877-877.	0.6	2
136	Expression Profiling for MEIS1 and HOXA9/10 Identifies an Increased Incidence of MLL Rearrangements in T-ALL: A Children's Oncology Group Study.. <i>Blood</i> , 2012, 120, 2505-2505.	0.6	0
137	Second Neoplasms After Treatment of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 661-661.	0.6	0
138	Neurocognitive outcome in survivors of pediatric cancer. <i>Current Opinion in Pediatrics</i> , 2011, 23, 27-33.	1.0	31
139	Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Blood</i> , 2011, 118, 243-251.	0.6	126
140	Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2011, 43, 237-241.	9.4	239
141	Childhood Femoral Head Osteonecrosis. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2011, 9, 2-12.	1.3	4
142	Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906. <i>Pediatric Blood and Cancer</i> , 2011, 57, 569-577.	0.8	55
143	Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232. <i>Blood</i> , 2011, 118, 1440-1440.	0.6	3
144	TREATMENT Toxicity in Adolescents and Young ADULT (AYA) PATIENTS COMPARED with Younger PATIENTS TREATED for HIGH RISK B-Precursor ACUTE LYMPHOBLASTIC LEUKEMIA (HR-ALL): A REPORT From the CHILDREN'S Oncology GROUP STUDY AALL0232. <i>Blood</i> , 2011, 118, 1510-1510.	0.6	12

#	ARTICLE	IF	CITATIONS
145	A BCR-ABL1-Like Gene Expression Profile Confers a Poor Prognosis In Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From Children's Oncology Group (COG) AALL0232. <i>Blood</i> , 2011, 118, 743-743.	0.6	3
146	iAMP21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) on Contemporary Children's Oncology Group (COG) Studies. <i>Blood</i> , 2011, 118, 739-739.	0.6	2
147	Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): Review from an international consensus conference. <i>Pediatric Blood and Cancer</i> , 2010, 54, 872-878.	0.8	22
148	Infant Acute Lymphoblastic Leukemias Are Pan-Sensitive to Obatoclox Across molecular/Cytogenetic Subtypes, Especially MLL-ENL, and gene Expression Profiles Determine Obatoclox IC50: A Report on the Children's Oncology Group (COG) P9407 Trial. <i>Blood</i> , 2010, 116, 2757-2757.	0.6	1
149	Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991. <i>Blood</i> , 2010, 116, 497-497.	0.6	1
150	Early Response Characteristics and Blast Cytogenetic Features In 5,377 Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): A Children's Oncology Group (COG) Study. <i>Blood</i> , 2010, 116, 414-414.	0.6	0
151	ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Blood</i> , 2010, 116, 8-8.	0.6	1
152	Nelarabine May Be Safely Incorporated Into a Phase III Study for Newly Diagnosed T-Lineage Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Blood</i> , 2010, 116, 865-865.	0.6	2
153	Average Absolute Neutrophil Count During Maintenance Chemotherapy In Latino Versus Non-Latino Caucasian Patients with Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 3237-3237.	0.6	0
154	Gene Expression Profiling Reveals Genes Predictive of Outcome In Infant Acute Lymphoblastic Leukemia (ALL) and Distinctive Age-Related Gene Expression Profiles (< 90 Days vs. > 90 Days): A Children's Oncology Group Study. <i>Blood</i> , 2010, 116, 412-412.	0.6	0
155	Is immunization necessary after therapy for acute lymphoblastic leukemia (ALL) has been completed?. <i>Pediatric Blood and Cancer</i> , 2009, 53, 922-923.	0.8	1
156	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.. <i>Blood</i> , 2009, 114, 1580-1580.	0.6	7
157	Report On Excessive Induction Toxicity in Infants with ALL Enrolled On COG Protocol AALL0631: A Children's Oncology Group Study.. <i>Blood</i> , 2009, 114, 3091-3091.	0.6	4
158	Patients with Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia (ALL) Have High Levels of Minimal Residual Disease (MRD) at the End of inductionâ€”A Children's Oncology Group (COG) Study.. <i>Blood</i> , 2009, 114, 9-9.	0.6	24
159	Specific MLL Partner Genes in Infant Acute Lymphoblastic Leukemia (ALL) Associated with Outcome Are Linked to Age and White Blood Cell Count (WBC) at Diagnosis: A Report On the Children's Oncology Group (COG) P9407 Trial.. <i>Blood</i> , 2009, 114, 907-907.	0.6	5
160	Secondary Chromosomal Abnormalities Appear to Be Less Prognostic for Children with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with Intensified Imatinib and Chemotherapy: Results of the Children's Oncology Group (COG) Study AALL0031.. <i>Blood</i> , 2009, 114, 2606-2606.	0.6	2
161	Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group.. <i>Blood</i> , 2009, 114, 2634-2634.	0.6	0
162	Amplification of AML1 Does Not Impact Early Outcome of Children with Acute Lymphoblastic Leukemia (ALL) Treated with Risk-Directed Chemotherapy: A Report From the Children's Oncology Group (COG).. <i>Blood</i> , 2009, 114, 2598-2598.	0.6	6

#	ARTICLE	IF	CITATIONS
163	Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Blood</i> , 2008, 111, 2984-2990.	0.6	41
164	Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. <i>Blood</i> , 2008, 111, 5477-5485.	0.6	751
165	Increased Incidence of Osteonecrosis (ON) with a Dexamethasone (DEX) Induction for High Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report from the Children's Oncology Group (COG).. <i>Blood</i> , 2008, 112, 898-898.	0.6	19
166	Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children's Oncology Group Study 1991. <i>Blood</i> , 2008, 112, 9-9.	0.6	12
167	Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Children's Oncology Group (COG) Study AALL0031.. <i>Blood</i> , 2008, 112, 911-911.	0.6	1
168	Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children's Oncology Group Study 1991. <i>Blood</i> , 2008, 112, 701-701.	0.6	1
169	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). <i>Blood</i> , 2007, 109, 926-935.	0.6	413
170	Isolated CNS Relapse of Acute Lymphoblastic Leukemia Treated With Intensive Systemic Chemotherapy and Delayed CNS Radiation: A Pediatric Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 3142-3149.	0.8	105
171	Double Delayed Intensification (DDI) Is Equivalent to Single DI (SDI) in Children with National Cancer Institute (NCI) Standard-Risk Acute Lymphoblastic Leukemia (SR-ALL) Treated on Children's Cancer Group (CCG) Clinical Trial 1991 (CCG-1991).. <i>Blood</i> , 2006, 108, 146-146.	0.6	11
172	Therapy of low-risk subsets of childhood acute lymphoblastic leukemia: When do we say enough?. <i>Pediatric Blood and Cancer</i> , 2005, 45, 876-880.	0.8	24
173	Pharmacogenetics of Minimal Residual Disease Response in Children with Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2004, 104, 451-451.	0.6	0
174	RAS mutations in pediatric leukemias with MLL gene rearrangements. , 1998, 21, 270-275.		32
175	Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia. , 1997, 79, 1049-1054.		47